Crohn's Disease and Colitis Trial, Not Yet Recruiting NCT07143188 Sponsor: Wake Forest University Health Sciences Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Not Yet Recruiting

NCT07143188
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults who have already been diagnosed with inflammatory bowel disease (either ulcerative colitis or Crohn's disease) and are currently being treated as an outpatient for a flare-up, meaning a noticeable worsening of symptoms such as stomach pain, nausea, vomiting, diarrhoea, joint pain, fever, bleeding, or unintended weight loss.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose flare-up is serious enough to require a hospital stay for treatment.
  • People who have allergies to any of the ingredients in the mBIOTA Elemental Diet.
  • People who are currently pregnant.
  • People who have diabetes and are currently using insulin as part of their treatment.
  • People whose other health conditions or personal circumstances would make it difficult to follow the elemental diet required by the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Richard B Weinberg, MD, Wake Forest University Health Sciences

Phone: 703-463-1287

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 September 2026
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

change of symptom burden scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov